Credits: Canva
Legionnaires Outbreak: Public health officials in London, Ontario, have redeclared a Legionnaires’ disease outbreak after 25 new cases emerged, weeks after declaring the situation under control. The Middlesex-London Health Unit (MLHU) confirmed Tuesday that testing has identified a likely source: cooling towers at Sofina Foods Inc., a large meat-processing facility on Trafalgar Street.
The outbreak was first detected in early July and by early August had led to 70 confirmed cases and three deaths. After three weeks without new infections, the MLHU declared the outbreak over on August 6. But within days, new patients began appearing.
As of this week, the caseload has climbed to 94, including 86 hospitalizations and four deaths. Six patients remain in hospital. Officials say the resurgence highlights how the bacteria can persist in contaminated environments despite earlier cleaning efforts.
“For several weeks, no additional illnesses were reported, and we were optimistic that remediation efforts had eliminated the bacteria. However, 25 more people have now become ill,” said Dr. Joanne Kearon, associate medical officer of health. “Fortunately, a likely source has now been identified.”
Read: Legionnaires Outbreak in New York: All That You Need To Know About The Disease
Extensive environmental testing linked the outbreak strain of Legionella bacteria to Sofina Foods’ cooling towers. Samples taken in recent weeks matched the same bacterial subtype found in patient cases.
While nine different cooling towers across the city initially tested positive for live bacteria, the Sofina plant produced a definitive genetic match. Earlier testing at the site in 2024 and early 2025 had shown no match, but officials said the bacteria can survive in cooling towers and regrow under hot, humid conditions.
The health unit emphasized that food products from Sofina remain safe to consume, since Legionnaires’ disease spreads only through inhaling contaminated water droplets, not through eating or drinking.
Sofina Foods, which employs hundreds of workers in London’s east end, said the new findings were “unexpected” given the company’s daily sanitation protocols and previous negative test results.
“We are deeply concerned with this new information and are continuing to investigate fully,” said Sharon Begley, Sofina’s chief safety officer. “Over and above our regular processes, we conducted further deep cleaning and disinfecting processes recommended by MLHU. The cooling tower is offline and will remain offline until these additional steps are completed.”
The company stressed its commitment to employee and community safety, noting it has been cooperating closely with public health authorities since the outbreak began.
Legionnaires’ disease is a severe form of pneumonia caused by Legionella bacteria. It is not transmitted from person to person. Instead, people get sick when they inhale mist or small droplets of water containing the bacteria, which can be carried by wind from sources such as cooling towers, hot tubs, and water systems.
Symptoms typically appear within 2 to 10 days of exposure and may include fever, chills, cough, muscle aches, and shortness of breath. Most exposed individuals do not get sick, but older adults, smokers, and people with weakened immune systems face greater risk of serious illness.
The current outbreak has been concentrated in a six-kilometre radius in London, with cases ranging from young adults to seniors. No children have been affected to date.
Also Read: Legionnaires' Outbreak Update: It Is No Longer 'Only A New York Problem'
Dr. Kearon warned that more cases could surface due to the bacteria’s incubation period. “Legionella has an incubation period of two to 10 days ... there may still be further cases in the next two weeks,” she said.
This year’s outbreak is already the largest in London’s recent history, surpassing a 2024 outbreak that caused 30 cases and two deaths. Officials say they are working with Sofina Foods and other operators to ensure thorough remediation and prevent further spread.
“The decision to reopen the outbreak reflects a rise in cases after several weeks without new cases, suggesting that the Legionella bacteria has re-emerged in the environment despite earlier remediation efforts,” MLHU said in a statement.
Also Read: Michael Clarke Reveals Skin Cancer Surgery, Sparking Urgent Reminder: How To Spot The Signs Early?
Credits: iStock
Health authorities in Australia have sounded the alarm after a traveller returning from Bali tested positive for measles, sparking concerns in communities south of Brisbane and reinforcing the urgent need for vaccination. The highly contagious viral illness, once considered largely under control in many developed countries, is making a troubling comeback in Australia with cases rising sharply in Queensland and Western Australia.
The alert follows an infected passenger’s arrival on Jetstar flight JQ60 into Brisbane on August 19, and subsequent visits to multiple public venues in Yamanto and Boonah while unknowingly infectious. While those locations are no longer considered a risk, people who were present during the identified times are being urged to monitor for symptoms for up to 18 days.
The infected individual landed at Brisbane Airport at 5:40 a.m. on August 19 before moving through the terminal until around 7:10 a.m. Later that day, they visited an Aldi supermarket in Yamanto, and in the following days, they attended a pharmacy and the Boonah Hospital emergency department.
Dr. Catherine Quagliotto, Public Health Physician at West Moreton Health, explained that while the virus does not remain in the environment long after an infected person has left, the exposure risk during the infectious window was significant. “Early signs can include fever, cough, runny nose and red or watery eyes, followed a few days later by a distinctive red, blotchy rash,” she said. Symptoms typically develop 7–10 days after exposure but can take as long as 18 days to appear.
Queensland Health has urged anyone who develops symptoms to stay home, seek testing, and contact their doctor or hospital ahead of arrival to avoid spreading the virus further.
The Brisbane case comes as Western Australia reports a worrying spike in measles. WA Health confirmed 13 cases in July and August 2025, including four linked to overseas travel and nine acquired locally. This represents a dramatic rise compared to just six cases across the entire state in 2024.
Dr. Paul Armstrong, Director of the Communicable Diseases Control Directorate, emphasized that vaccination remains the cornerstone of protection. “Measles is highly infectious and can cause serious illness, particularly in babies and young children, and often requires hospitalisation and, in rare cases, blindness or even death,” he said.
The outbreak is closely tied to international travel. Popular holiday destinations such as Indonesia, India, Vietnam, and other parts of South and Southeast Asia continue to report high numbers of measles cases, making travellers a key factor in reintroducing the virus to Australia.
Measles is far more than just a childhood illness. Caused by a virus that spreads through airborne droplets from coughing and sneezing, it is one of the most contagious diseases known. A single infected person can pass it on to up to 90% of unvaccinated people in close contact.
While most individuals recover within a week of developing the characteristic rash, measles can lead to severe complications. These include pneumonia, encephalitis (brain inflammation), hearing loss, and in rare but devastating cases, death. Pregnant women, infants, and people with weakened immune systems are especially vulnerable.
Measles progresses in stages. The first signs usually resemble a common cold: fever, cough, runny nose, and red, watery eyes. Within a few days, small white spots may appear inside the mouth, followed by the hallmark red, blotchy rash that typically spreads from the face downward across the body.
Crucially, people are contagious even before the rash develops—about five to six days before symptoms appear and up to four days after. This makes containing outbreaks extremely challenging, particularly in busy international hubs like airports.
Australia maintains one of the world’s strongest vaccination programs, with more than 93% of children over age five fully immunised against measles. The standard schedule includes two doses of the measles-mumps-rubella (MMR) vaccine, given at 12 months and 18 months of age.
However, gaps remain. Adults born after 1965 who missed doses, migrants from countries with weaker immunisation programs, and people who are immunocompromised represent at-risk groups. The Australian government continues to offer free catch-up vaccines for adults under 20 and for people arriving for humanitarian reasons.
“Adults aged between 30 to 60 years should get vaccinated if they do not have evidence of two doses of a measles vaccine,” Dr. Armstrong advised. He also noted that infants as young as six months can receive the vaccine early if traveling to high-risk areas.
Importantly, there is no booster requirement for those who have already had two doses, and people who have previously contracted measles are considered immune for life.
The resurgence of measles in Australia mirrors trends worldwide. After years of steady progress toward elimination, the World Health Organization has reported rising cases across Asia, Africa, and parts of Europe. Pandemic-related disruptions to immunisation programs have left millions of children unprotected, fueling outbreaks in countries that had previously made strides against the disease.
Travel plays a key role in this resurgence. With international tourism rebounding strongly after COVID-19, Australians returning from popular destinations like Bali are now at increased risk of both contracting and importing measles.
Authorities in Queensland and WA are working swiftly to contain the spread. Public alerts about exposure sites, targeted communication campaigns, and free vaccine programs are all part of a coordinated response. Health professionals emphasize that personal responsibility—staying home when sick, seeking timely medical advice, and checking vaccination status—is equally critical.
Dr. Quagliotto put it simply: “Vaccination offers the best protection for both individuals and the community.”
If you’re planning travel to measles affected regions or even in general, consult your doctor about vaccination well in advance. Parents with young children should be aware that infants may need an accelerated vaccination schedule.
On return, any flu-like symptoms coupled with rash development should prompt immediate medical attention. Always call ahead before visiting a healthcare facility, and wear a mask to prevent spreading the virus.
The measles alert south of Brisbane is a reminder that even in countries with high vaccination rates, the virus can re-emerge through international travel. With Australia now reporting more cases in 2025 than in recent years combined, vigilance is essential.
Credits: Instagram/Michael Clarke
Former Australian cricket captain Michael Clarke has once again faced a health struggle that affects millions around the globe, skin cancer. Clarke, 44, posted on social media that he recently had surgery to have a suspicious growth removed from his nose. His post was not just about healing, but also an appeal: get your skin checked.
This reminder from a sports legend underscores a pressing global health issue. Skin cancer is the most common cancer diagnosed in the United States, Australia, and many other parts of the world. The good news is that when detected early, most cases are highly treatable but that early detection depends on awareness knowing what skin cancer looks like and when to seek medical help.
Clarke's recent diagnosis is not his initial experience with skin cancer. In 2006, doctors operated on him to remove suspicious marks on his face and chest. They removed them surgically before they were able to do further damage. Again in 2019, he had surgery to have cancerous tumors removed from his forehead.
Now, in 2025, his post-surgery update again emphasizes how skin cancer can be a recurring aspect for those at risk. Clarke had penned, "Skin cancer is real! Particularly in Australia. Another one removed from my nose today. A friendly reminder to have your skin checked. Prevention is better than the cure but in my case, regular check-ups and early detection is the key."
Australia has some of the highest rates of skin cancer on the planet because of high levels of UV radiation. However, Clarke's experience sounds off far beyond his native soil. In the United States alone, more than 5 million instances of skin cancer are treated annually, the American Cancer Society says.
Skin cancer occurs when skin cells grow out of control, penetrating surrounding tissue and occasionally spreading to other organs. The sun's ultraviolet (UV) light is the primary cause, though indoor tanning is also a culprit. There are three types of skin cancer with varying risks and appearances:
Basal Cell Carcinoma (BCC): The most frequent one. BCC typically appears as a flesh-colored bump, pearl-like growth, or pinkish lesion. It usually develops on sun-exposed sites such as the face, neck, and arms. Although it does not spread much, if left untreated, it can produce extensive local destruction.
Squamous Cell Carcinoma (SCC): The second most frequent type. SCC can be a hard red bump, scaly area, or sore that closes up and reopens. It often occurs on sun-exposed areas like the ears, lips, and face. If left alone, SCC can grow and invade deeper tissues.
Melanoma: The most life-threatening form. Melanoma can develop in a pre-existing mole or as a new dark spot that appears different from surrounding markings. It grows more quickly than other skin cancers, so catching it early is paramount.
SCC can develop from a precancerous skin growth: Actinic keratoses are primarily caused by cumulative sun exposure and tend to develop on areas of the body that get the most sunlight, including the face, scalp, neck, hands, and forearms. People with fair skin are more likely to develop these patches, but they can occur in anyone with a history of significant sun exposure.
One of the difficulties with skin cancer is that its early signs are simple to overlook or assume to be harmless. However, being in a position to recognize these alterations can be the difference between life and death. General warning signals are:
Doctors recommend following the ABCDE rule for melanoma:
Asymmetry: One half doesn’t match the other.
Border: Edges are irregular or blurred.
Color: Uneven colors—brown, black, red, or white patches.
Diameter: Larger than 6mm (about the size of a pencil eraser).
Evolving: Any mole or spot that changes in shape, size, or symptoms.
Most individuals think that skin cancer only occurs on sun-exposed skin. Although it is correct that the scalp, face, neck, arms, and hands are the most susceptible, cancers can occur on less visible locations:
This is particularly the case for individuals with darker skin. In these individuals, melanoma and other types tend to appear on less sun-exposed areas, i.e., under nails or on the feet.
Anyone may get skin cancer, but certain individuals have a higher risk based on specific characteristics. People with fair skin, light hair, and light eyes are at greater risk, as are those with past histories of severe sunburns, particularly blistering. Frequent sun exposure with poor protection and tanning bed use also increase the risk of skin cancer. An inheritance pattern of the illness or compromised immune system further increases the risk. Michael Clarke's years of cricket playing in the strong Australian sunlight emphasize how long-term exposure to the sun can dramatically raise the risk of skin cancer.
While you cannot alter your genes or your skin type, you can lower your risk considerably:
Clarke's focus on early diagnosis is echoed in medical guidance: the sooner you detect changes, the greater the potential for effective treatment.
Skin cancer often develops silently. A small bump today may not cause pain but could evolve into something dangerous over time. Clarke’s case illustrates why vigilance is critical even after previous treatments. Recurrence is possible, and only regular screenings can catch issues before they progress.
The American Academy of Dermatology recommends annual full-body skin checks for most adults, and more frequent exams for those with higher risk factors.
Michael Clarke's candor regarding his diagnosis puts a spotlight on a public health problem that affects the entire world. His tale is not merely that of an athlete undergoing another surgery it is a reminder to all, wherever they may be in the world, that skin cancer exists, is prevalent, and is frequently preventable.
Credits: Canva
Eli Lilly has taken a major step in the fight against obesity and diabetes. The company announced that its oral GLP-1 drug, orforglipron, successfully met the “primary and all key secondary endpoints” in a large clinical trial, paving the way for global regulatory submissions.
“With these positive data in hand, we are moving with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting,” said Kenneth Custer, Eli Lilly’s executive vice president and president of cardiometabolic health.
“If approved, we are ready to offer a convenient, once-daily pill that can be scaled globally, removing barriers and redefining how obesity is treated around the world.”
Orforglipron is an investigational, non-peptide, once-daily small molecule GLP-1 receptor agonist. Unlike some oral medications that come with strict food or water restrictions, it can be taken at any time of day without such limitations.
Originally discovered by Japan’s Chugai Pharmaceutical and later licensed to Eli Lilly in 2018, orforglipron is now in Phase 3 trials. The company is testing it not just for weight management and type 2 diabetes but also for conditions linked to obesity, including obstructive sleep apnea and hypertension.
The company’s latest clinical trial, called ATTAIN-2, produced results that have drawn significant attention. At the highest dose: 36 mg daily for 72 weeks, participants saw an average weight loss of 22.9 pounds (10.5%), compared to just 5.1 pounds (2.2%) among those given a placebo.
The drug also delivered strong results for people with type 2 diabetes. Across doses, orforglipron reduced A1C levels by 1.3% to 1.8% from a baseline of 8.1%. Notably, 75% of participants who took the highest dose achieved an A1C of 6.5% or below, aligning with the American Diabetes Association’s definition of diabetes remission.
Beyond weight and blood sugar, orforglipron showed broader health benefits. The trial reported improvements in cardiovascular risk factors such as non-HDL cholesterol, systolic blood pressure, and triglyceride levels. In an exploratory analysis, the drug also cut high-sensitivity C-reactive protein, a key marker of inflammation, by about 50%.
Injectable GLP-1 receptor agonists like semaglutide and tirzepatide have already transformed obesity and diabetes care, but accessibility remains a hurdle. For many patients, injections are intimidating, inconvenient, or simply not practical in daily life.
That’s where an oral pill could be a game-changer. A once-daily tablet could remove psychological and logistical barriers, making it easier for patients to stay on treatment. And given the rising global burden of obesity, which significantly raises the risk of cardiovascular disease, stroke, and some cancers, the demand for more convenient treatment options has never been greater.
The big question now is whether oral GLP-1 drugs are as effective as their injectable counterparts.
A 2021 research review published in Springer Nature, offers some clues. After examining multiple studies, researchers concluded that oral semaglutide, a similar class of drug, provided “similar or better efficacy and similar tolerability” compared to injectable GLP-1 receptor agonists.
Also Read: How To Identify A Counterfeit Ozempic? Look For These Signs
In some cases, oral versions were found to be just as effective for weight loss and lowering A1C levels in people with type 2 diabetes. However, the review focused on patients already using insulin, which may have influenced outcomes. Experts emphasize that while results are encouraging, more research is still needed to directly compare oral and injectable versions in broader populations.
For now, injections remain the gold standard in clinical practice. Drugs like Wegovy and Mounjaro (both injectables) have shown weight reductions of 15% to 20% or more in major trials, higher than the 10.5% seen with orforglipron in ATTAIN-2. That said, the convenience of a pill could tip the balance for many patients, especially those reluctant to use injections long-term.
Eli Lilly’s oral GLP-1 drug is not yet approved, but the latest results highlight its potential to reshape treatment strategies for obesity.
© 2024 Bennett, Coleman & Company Limited